Kazia Therapeutics Limited 

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and the University of Newcastle. Kazia Therapeutics Limited also has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug paxalisib in primary central nervous system lymphoma; Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083; and Joan & Sanford I Weill Medical College of Cornell University for Phase II clinical study using Paxalisib in combination with ketogenic diet for glioblastoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.